Risk indicators of preventable morbidity related to drug utilization

被引:16
作者
Dago Martinez, Ana [1 ]
Arcos Gonzalez, Pedro [1 ]
de Toledo Saavedra, Flor Alvarez [1 ]
Baena Parejo, Maria Isabel [2 ]
Martinez Olmos, Jose [2 ]
Gorostiza Ormaetxe, Inigo [3 ]
机构
[1] Univ Oviedo, Dept Med, Area Med Prevent & Salud Publ, E-33006 Oviedo, Spain
[2] Univ Granada, Grp Invest Atenc Farmaceut, Granada, Spain
[3] Red Espanola Atenc Primaria, Madrid, Spain
关键词
pharmaceutical care; presentable morbidity; Delphi technique; medication indicators;
D O I
10.1157/13099118
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: To select clinical situations that can be used as risk indicators of preventable morbidity caused by drugs at the community pharmacies, and to study their acceptability, in terms of pertinence and relevance. Methods: We used the Delphi technique, in 2 rounds, by a panel of 14 medical doctors and pharmacists experts, to study the relevance of 68 types of clinical situations as risk indicators of preventable morbidity related to drug utilization used by health professionals in community pharmacies, with scientific evidence of foreseeable adverse result, frequent situations in ambulatory care and with controllable cause and result. Results: 43 of the 68 indicators were considered usable and pertinent. The indicators referred three areas: drug type (medications of narrow therapeutic margin, with individualized dose and adverse reactions frequent and severe), health problem (chronic problems, especially asthma, cardiac, thyroid and prostate illness, and pain), and patient (old or with several medications. Pharmacists systematically overvalued some indicators in relation to the doctors, but differences were not significant. Conclusions: Forty-three indicators were selected as valuable to identify situations of preventable morbidity related to drug utilization.
引用
收藏
页码:29 / 36
页数:8
相关论文
共 34 条
[1]  
ALONSO P, 2002, FARM HOSP, V26, P76
[2]  
Astigarraga E., 2005, METODO DELPHI
[3]  
Baena MI, 2001, PHARM CARE ESP, V3, P345
[4]   INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION [J].
BATES, DW ;
CULLEN, DJ ;
LAIRD, N ;
PETERSEN, LA ;
SMALL, SD ;
SERVI, D ;
LAFFEL, G ;
SWEITZER, BJ ;
SHEA, BF ;
HALLISEY, R ;
VANDERVLIET, M ;
NEMESKAL, R ;
LEAPE, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (01) :29-34
[5]  
Campbell SM, 2000, BRIT MED J, V321, P1
[6]  
Cantrill J.A., 1996, INT J PHARM PRACT, V4, P67, DOI DOI 10.1111/J.2042-7174.1996.TB00844.X
[7]   Adverse drug events as a cause of hospital admission in the elderly [J].
Chan, M ;
Nicklason, F ;
Vial, JH .
INTERNAL MEDICINE JOURNAL, 2001, 31 (04) :199-205
[8]  
*COM CONS, 2002, ARS PHARM, V43, P175
[9]   Validation of four clinical indicators of preventable drug-related morbidity [J].
Flanagan, PS ;
MacKinnon, NJ ;
Bowles, SK ;
Kirkland, SA .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (01) :20-24
[10]   Adverse drug events in ambulatory care [J].
Gandhi, TK ;
Weingart, SN ;
Borus, J ;
Seger, AC ;
Peterson, J ;
Burdick, E ;
Seger, DL ;
Shu, K ;
Federico, F ;
Leape, LL ;
Bates, DW .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (16) :1556-1564